ClinicalTrials.Veeva

Menu
IMA Clinical Research | Albuquerque Neuroscience logo

IMA Clinical Research | Albuquerque Neuroscience

Research site

Site insights

Top conditions

Top treatments

Rimegepant
Bapineuzumab
ATH-1017
ALTO-100
Sodium Oxybate
SPD489
Orforglipron
Agomelatine
ELND005
Xyrem®

Parent organization

This site is a part of IMA Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Sofia Miranda

Verified by this site

Active trials

19 of 68 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Status recently updated

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Enrolling
Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo
Locations recently updated

TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects...

Enrolling
Alcohol Use Disorder (AUD)
Drug: TMP-301
Drug: Placebo

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Active, not recruiting
Shingles
Human
Biological: Selected Vaccine Candidate group (Dose level, Schedule)
Biological: Shingrix - SSB

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients wi...

Enrolling
Bipolar Disorder I or II with a Major Depressive Episode
Drug: Placebo
Drug: ALTO-100

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fase...

Enrolling
Social Anxiety Disorder (SAD)
Drug: Fasedienol Nasal Spray
Drug: Placebo Nasal Spray

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidep...

Active, not recruiting
Major Depressive Disorder
Drug: ALTO-100
Drug: Placebo

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

Trial sponsors

Lilly logo
Pfizer logo
Shire logo
Allergan logo
Bristol-Myers Squibb (BMS) logo
Janssen (J&J Innovative Medicine) logo
V
Abbott logo
Akili Interactive Labs logo
Alto Neuroscience logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems